Blog Header

By: Adam Hansard

June 4, 2018

Syntimmune to Present at Jefferies 2018 Global Healthcare Conference

Read Story
May 17, 2018

Syntimmune Announces Positive Preliminary Results from Clinical Proof-of-Concept Trial of SYNT001 in Pemphigus Vulgaris and Foliaceus

Read Story
April 25, 2018

Syntimmune Appoints Andrew Cheng, M.D., Ph.D., to Board of Directors, Bolstering Clinical Development Expertise

Read Story
February 26, 2018

Data on Lead Program SYNT001 to be Presented at Plenary Session of International Investigative Dermatology Conference

Read Story
January 3, 2018

Syntimmune Appoints Jean-Paul Kress, M.D., as President and Chief Executive Officer

Read Story
December 11, 2017

American Society of Hematology (ASH) Presentation December 11th, 2017

Read Story
November 1, 2017

Syntimmune Announces Clinical Data from First-in-Human Trial of Lead Candidate SYNT001

Read Story
June 21, 2017

Syntimmune Closes $50 Million Series B Financing led by Apple Tree Partners

Read Story
March 20, 2017

Syntimmune Announces Breakthrough Results of FcRn Inhibition Published in PNAS

Read Story
March 25, 2016

Syntimmune Secures Second Tranche of $26 Million Series A Financing

Read Story